Robert E. Hollingsworth

4.9k citations

66 papers · 3.7k indexed · 1 hit paper · h-index 32

Co-authors: Kathrin U. Jansen Robert A. Sclafani Kris F. Sachsenmeier Erin Sult David Dolberg Mina J. Bissell Manfred J. Lohka Yuewei Qian
Topics: Cancer Cells and Metastasis (7 papers)Immunotherapy and Immune Responses (7 papers)Ubiquitin and proteasome pathways (7 papers)
Cited by: Oncology Immunology Physiology
Journals: Nature Science Proceedings of the National Academy of Sciences
Partner nations: United States United Kingdom Canada

In The Last Decade

Robert E. Hollingsworth

64 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Turning the corner on therapeutic cancer vaccines

2019 530 citations Robert E. Hollingsworth et al. profile →

Peers

Countries citing papers authored by Robert E. Hollingsworth

Since Specialization

Citations

This map shows the geographic impact of Robert E. Hollingsworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Hollingsworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Hollingsworth more than expected).

Fields of papers citing papers by Robert E. Hollingsworth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Hollingsworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Hollingsworth. The network helps show where Robert E. Hollingsworth may publish in the future.

Co-authorship network of co-authors of Robert E. Hollingsworth

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Hollingsworth. A scholar is included among the top collaborators of Robert E. Hollingsworth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Hollingsworth. Robert E. Hollingsworth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model 2021 ·Molecular Cancer Research ·Rajaâ El Meskini,(unknown),(unknown),(unknown),(unknown),Nathan Pate,(unknown),Michael D. Oberst,Ian M. Kaplan,Patrick Raber,Terry Van Dyke,Shyam K. Sharan,Robert E. Hollingsworth,Chi‐Ping Day,Glenn Merlino,Zoë Weaver Ohler	3
2	Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies 2017 ·Cancer Research ·Jonathan Rios‐Doria,Jay Harper,Raymond Rothstein,Leslie Wetzel,Jon Chesebrough,(unknown),Cui Chen,(unknown),Kathy Mulgrew,Kelly McGlinchey,Ryan Fleming,Binyam Bezabeh,John Meekin,David J. Stewart,(unknown),Philip Martin,Andrew Buchanan,Nazzareno Dimasi,Emil F. Michelotti,Robert E. Hollingsworth	91
3	A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors 2016 ·Cancer Research ·Haihong Zhong,April Davis,Maria Ouzounova,Rosa A. Carrasco,Cui Chen,Shannon Breen,Yong S. Chang,Jiaqi Huang,Zheng Liu,Yihong Yao,Elaine M. Hurt,Jacques Moisan,Michael Fung,David A. Tice,Shawn G. Clouthier,Zhan Xiao,Max S. Wicha,Hasan Körkaya,Robert E. Hollingsworth	40
4	5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma 2016 ·Clinical Cancer Research ·Samuel A. Kerk,(unknown),Alexander T. Pearson,Kristy A. Warner,Zhaocheng Zhang,Felipe Nör,Vivian Petersen Wagner,Pablo Agustín Vargas,Max S. Wicha,Elaine M. Hurt,Robert E. Hollingsworth,David A. Tice,Jacques E. Nör	40
5	A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response 2016 ·Molecular Cancer Therapeutics ·Zhan Xiao,Rosa A. Carrasco,Kevin Schifferli,Krista Kinneer,Ravinder Tammali,Hong Chen,(unknown),Leslie Wetzel,Chunning Yang,Partha S. Chowdhury,Ping Tsui,Philipp Steiner,Bahija Jallal,Ronald Herbst,Robert E. Hollingsworth,David A. Tice	27
6	HER2 drives Mucin-like 1 to control proliferation in breast cancer cells 2016 ·Oncogene ·Sarah J. Conley,Emily E. Bosco,David A. Tice,Robert E. Hollingsworth,Roy S. Herbst,Xiao Zhang	31
7	Interleukin-6 Stimulates Defective Angiogenesis 2015 ·Cancer Research ·Ganga Gopinathan,Carla Milagre,Oliver M.T. Pearce,Louise E. Reynolds,Kairbaan Hodivala‐Dilke,David A. Leinster,Haihong Zhong,Robert E. Hollingsworth,R. Thompson,James R. Whiteford,Frances R. Balkwill	191
8	Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer 2015 ·Cancer Research ·Carla Milagre,Ganga Gopinathan,(unknown),Richard G. Thompson,Hagen Kulbe,Haihong Zhong,Robert E. Hollingsworth,Richard Grose,David D.L. Bowtell,Daniel Hochhauser,Frances R. Balkwill	36
9	Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models 2015 ·Neoplasia ·Jonathan Rios‐Doria,Nicholas M. Durham,Leslie Wetzel,Raymond Rothstein,Jon Chesebrough,Nicholas Holoweckyj,Wei Zhao,Ching Ching Leow,Robert E. Hollingsworth	146
10	Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling 2015 ·Molecular Cancer ·Alan M. Sandercock,(unknown),Sandrine Guillard,Kris F. Sachsenmeier,(unknown),Carl Hay,(unknown),Qihui Huang,Kuan Yan,Bram Herpers,Leo Price,Jo Soden,Jim Freeth,Lutz Jermutus,Robert E. Hollingsworth,Ralph Minter	35
11	MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas 2014 ·Molecular Cancer Therapeutics ·Haihong Zhong,Christine Fazenbaker,Shannon Breen,Cui Chen,Jiaqi Huang,Christopher Morehouse,Yihong Yao,Robert E. Hollingsworth	20
12	Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy 2013 ·Clinical Cancer Research ·Hemant K. Bid,Cheryl A. London,(unknown),Haihong Zhong,Robert E. Hollingsworth,Soledad Fernández,Xiaokui Mo,Peter J. Houghton	18
13	Development of a Novel Ectonucleotidase Assay Suitable for High-Throughput Screening 2012 ·SLAS DISCOVERY ·Kris F. Sachsenmeier,Carl Hay,(unknown),Lori Clarke,Kim Rosenthal,Sandrine Guillard,(unknown),Ralph Minter,Robert E. Hollingsworth	15
14	The Relative Activity of “Function Sparing” HIV-1 Entry Inhibitors on Viral Entry and CCR5 Internalization: Is Allosteric Functional Selectivity a Valuable Therapeutic Property? 2008 ·Molecular Pharmacology ·Vanessa Muniz‐Medina,Stacey A. Jones,Jodi M. Maglich,Cristin M. Galardi,Robert E. Hollingsworth,Wieslaw M. Kazmierski,Robert G. Ferris,Mark Edelstein,Karen Chiswell,Terry Kenakin	57
15	Apoptotic Regulation by the Crk Adapter Protein Mediated by Interactions with Wee1 and Crm1/Exportin 2002 ·Molecular and Cellular Biology ·J. Joshua Smith,(unknown),(unknown),Minoru Yoshida,Robert E. Hollingsworth,Sally Kornbluth	30
16	PTCH2, a novel human patched gene, undergoing alternative splicing and up-regulated in basal cell carcinomas. 1999 ·PubMed ·Peter G. Zaphiropoulos,Anne Birgitte Undén,Fahimeh Rahnama,Robert E. Hollingsworth,Rune Toftgård	69
17	A human homolog of the yeast CDC7 gene is overexpressed in some tumors and transformed cell lines 1998 ·Gene ·(unknown),Roger F. Drong,(unknown),Jerry L. Slightom,Robert A. Sclafani,Robert E. Hollingsworth	54
18	Yeast pre-meiotic DNA replication utilizes mitotic origin ARS1 independently of CDC7 function 1993 ·Chromosoma ·Robert E. Hollingsworth,Robert A. Sclafani	26
19	Integration of cell cycle control with transcriptional regulation by the retinoblastoma protein 1993 ·Current Opinion in Cell Biology ·Robert E. Hollingsworth,Phang‐Lang Chen,Wen‐Hwa Lee	74
20	Tumor Suppressor Genes: New Prospects for Cancer Research 1991 ·JNCI Journal of the National Cancer Institute ·Robert E. Hollingsworth,(unknown)	66

About Robert E. Hollingsworth

Robert E. Hollingsworth is a scholar working on Oncology, Physiology and Immunology, having authored 66 papers that have together received 3.7k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (7 papers), Immunotherapy and Immune Responses (7 papers) and Ubiquitin and proteasome pathways (7 papers). The work is most often cited by research in Oncology (1.4k citations), Immunology (942 citations) and Physiology (178 citations). Robert E. Hollingsworth has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Kathrin U. Jansen, Robert A. Sclafani, Kris F. Sachsenmeier, Erin Sult, David Dolberg, Mina J. Bissell, Manfred J. Lohka, Yuewei Qian, Eva Y.-H.P. Lee and Jean Gautier. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact